About file location

As the EGA is co-managed by the EMBL-EBI and CRG, files could be located in the UK and/or Spain, as indicated by their respective flags.

Alternatively, files could be located in one of the international Federated EGA nodes, as indicated next to the node's flag.
Need Help?

EBV-DLBCL by whole-genome and targeted amplicon-based sequencing

Whole genome sequencing data of EBV associated DLBCL of 8 matched tumor-normal patients. Additionally, targeted resequencing data of 47 patients is provided.

Request Access

DUO:0000006
version: 2019-01-07

health or medical or biomedical research

This data use permission indicates that use is allowed for health/medical/biomedical purposes; does not include the study of population origins or ancestry.

DUO:0000014
version: 2019-01-07

research use only

This data use limitation indicates that use is limited to research purposes (e.g., does not include its use in clinical care).

DUO:0000018
version: 2019-01-07

not for profit, non commercial use only

This data use modifier indicates that use of the data is limited to not-for-profit organizations and not-for-profit use, non-commercial use.

DUO:0000026
version: 2019-01-07

user specific restriction

This data use modifier indicates that use is limited to use by approved users.

DUO:0000028
version: 2019-01-07

institution specific restriction

This data use modifier indicates that use is limited to use within an approved institution.

This policy is adjusted from the Example DAA template at https://www.ebi.ac.uk/ega/submission/data_access_committee/policy_documentation#DAA, i.e. https://www.ebi.ac.uk/ega/sites/ebi.ac.uk.ega/files/documents/Example_DAA_Oct_2018.doc

DATA ACCESS AGREEMENT These terms and conditions govern access to the managed access datasets (details of which are set out in Appendix I) to which the User Institution has requested access. The User Institution agrees to be bound by these terms and conditions. Definitions Authorised Personnel: The individuals at the User Institution to whom the EBV-DLBCL Cancer Data Committee grants access to the Data. This includes the User, the individuals listed in Appendix II and any other individuals for whom the User Institution subsequently requests access to the Data. Details of the initial Authorised Personnel are set out in Appendix II. Data: The managed access datasets to which the User Institution has requested access. Data Producers: EBV-DLBCL Cancer Data Committee and the collaborators listed in Appendix I responsible for the development, organisation, and oversight of these Data. The EBV-DLBCL Cancer Data Committee (hauke.busch@uni-luebeck.de). External Collaborator: A collaborator of the User, working for an institution other than the User Institution. Project: The project for which the User Institution has requested access to these Data. A description of the Project is set out in Appendix II. Publications: Includes, without limitation, articles published in print journals, electronic journals, reviews, books, posters and other written and verbal presentations of research. Research Participant: An individual whose data form part of these Data. Research Purposes: Shall mean research that is seeking to advance the understanding of genetics and genomics, including the treatment of disorders, and work on statistical methods that may be applied to such research. User: The principal investigator for the Project. User Institution(s): The Institution that has requested access to the Data. XXXXX: Your Institution details here 1. The User Institution agrees to only use these Data for the purpose of the Project (described in Appendix II) and only for Research Purposes. The User Institution further agrees that it will only use these Data for Research Purposes which are within the limitations (if any) set out in Appendix I. 2. The User Institution agrees to preserve, at all times, the confidentiality of these Data. In particular, it undertakes not to use, or attempt to use these Data to compromise or otherwise infringe the confidentiality of information on Research Participants. Without prejudice to the generality of the foregoing, the User Institution agrees to use at least the measures set out in Appendix I to protect these Data. 3. The User Institution agrees to protect the confidentiality of Research Participants in any research papers or publications that they prepare by taking all reasonable care to limit the possibility of identification. 4. The User Institution agrees not to link or combine these Data to other information or archived data available in a way that could re-identify the Research Participants, even if access to that data has been formally granted to the User Institution or is freely available without restriction. 5. The User Institution agrees only to transfer or disclose these Data, in whole or part, or any material derived from these Data, to the Authorised Personnel. Should the User Institution wish to share these Data with an External Collaborator, the External Collaborator must complete a separate application for access to these Data. 6. The User Institution agrees that the Data Producers, and all other parties involved in the creation, funding or protection of these Data: a) make no warranty or representation, express or implied as to the accuracy, quality or comprehensiveness of these Data; b) exclude to the fullest extent permitted by law all liability for actions, claims, proceedings, demands, losses (including but not limited to loss of profit), costs, awards damages and payments made by the Recipient that may arise (whether directly or indirectly) in any way whatsoever from the Recipient’s use of these Data or from the unavailability of, or break in access to, these Data for whatever reason and; c) bear no responsibility for the further analysis or interpretation of these Data. 7. The User Institution agrees to follow the Fort Lauderdale Guidelines (http://www.wellcome.ac.uk/stellent/groups/corporatesite/@policy_communications/documents/web_document/wtd003207.pdf ) and the Toronto Statement (http://www.nature.com/nature/journal/v461/n7261/full/461168a.html). This includes but is not limited to recognising the contribution of the Data Producers and including a proper acknowledgement in all reports or publications resulting from the use of these Data. 8. The User Institution agrees to follow the Publication Policy in Appendix III. This includes respecting the moratorium period for the Data Producers to publish the first peer-reviewed report describing and analysing these Data. 9. The User Institution agrees not to make intellectual property claims on these Data and not to use intellectual property protection in ways that would prevent or block access to, or use of, any element of these Data, or conclusion drawn directly from these Data. 10. The User Institution can elect to perform further research that would add intellectual and resource capital to these data and decide to obtain intellectual property rights on these downstream discoveries. In this case, the User Institution agrees to implement licensing policies that will not obstruct further research and to follow the U.S. National Institutes of Health Best Practices for the Licensing of Genomic Inventions (2005) (https://www.icgc.org/files/daco/NIH_BestPracticesLicensingGenomicInventions_2005_en.pdf ) in conformity with the Organisation for Economic Co-operation and Development Guidelines for the Licensing of the Genetic Inventions (2006) (http://www.oecd.org/science/biotech/36198812.pdf ). 11. The User Institution agrees to destroy/discard the Data held, once it is no longer used for the Project, unless obliged to retain the data for archival purposes in conformity with audit or legal requirements. 12. The User Institution will notify the EBV-DLBCL Cancer Data Committee within 30 days of any changes or departures of Authorised Personnel. 13. The User Institution will notify the EBV-DLBCL Cancer Data Committee prior to any significant changes to the protocol for the Project. 14. The User Institution will notify the EBV-DLBCL Cancer Data Committee as soon as it becomes aware of a breach of the terms or conditions of this agreement. 15. The EBV-DLBCL Cancer Data Committee may terminate this agreement by written notice to the User Institution. If this agreement terminates for any reason, the User Institution will be required to destroy any Data held, including copies and backup copies. This clause does not prevent the User Institution from retaining these data for archival purpose in conformity with audit or legal requirements. 16. The User Institution accepts that it may be necessary for the Data Producers to alter the terms of this agreement from time to time. As an example, this may include specific provisions relating to the Data required by Data Producers other than the EBV-DLBCL Cancer Data Committee. In the event that changes are required, the Data Producers or their appointed agent will contact the User Institution to inform it of the changes and the User Institution may elect to accept the changes or terminate the agreement. 17. If requested, the User Institution will allow data security and management documentation to be inspected to verify that it is complying with the terms of this agreement. 18. The User Institution agrees to distribute a copy of these terms to the Authorised Personnel. The User Institution will procure that the Authorised Personnel comply with the terms of this agreement. 19. This agreement (and any dispute, controversy, proceedings or claim of whatever nature arising out of this agreement or its formation) shall be construed, interpreted and governed by the laws of Germany and shall be subject to the exclusive jurisdiction of German courts. Agreed for User Institution Signature: Name: Title: Date: Principal Investigator I confirm that I have read and understood this Agreement. Signature: Name: Title: Date: Agreed for XXXXX Signature: Name: Title: Date: APPENDIX I – DATASET DETAILS APPENDIX II ––PROJECT DETAILS APPENDIX III –– PUBLICATION POLICY APPENDIX I – DATASET DETAILS (to be completed by the data producer before passing to applicant) Dataset reference (EGA Study ID and Dataset Details) Name of project that created the dataset Names of other data producers/collaborators Axel Künstner (Axel.Kuenstner@uni-luebeck.de) Niklas Gebauer (Niklas.Gebauer@uksh.de) * Hauke Busch (Hauke.Busch@uni-luebeck.de) * Constitute the Data Access Committee Specific limitations on areas of research Minimum protection measures required File access: Data can be held in unencrypted files on an institutional compute system, with Unix user group read/write access for one or more appropriate groups but not Unix world read/write access behind a secure firewall. Laptops holding these data should have password protected logins and screenlocks (set to lock after 5 min of inactivity). If held on USB keys or other portable hard drives, the data must be encrypted. APPENDIX II – PROJECT DETAILS (to be completed by the Requestor) Details of dataset requested i.e., EGA Study and Dataset Accession Number Brief abstract of the Project in which the Data will be used (500 words max) All Individuals who the User Institution to be named as registered users Name of Registered User Email Job Title Supervisor* All Individuals that should have an account created at the EGA Name of Registered User Email Job Title APPENDIX III – PUBLICATION POLICY The EBV-DLBCL Cancer data producers and collaborators named in Appendix I intend to publish the results of their analysis of this dataset in a peer-reviewed journal and do not consider its deposition into public databases to be the equivalent of such publications. The data producers anticipate that the dataset could be useful to other qualified researchers for a variety of purposes. However, some areas of work are subject to a publication moratorium. The publication moratorium covers any publications (including oral communications) that describe the use of the dataset. For research papers, submission for publication should not occur until peer-reviewed journal publication of the EGA study unless the EBV-DLBCL Cancer Data Committee has provided written consent to earlier submission. In any publications based on these data, please describe how the data can be accessed, including the name of the hosting database (e.g., The European Genome-phenome Archive at the European Bioinformatics Institute) and its accession numbers (e.g., EGAS00000000029), and acknowledge its use in a form agreed by the User Institution with the EBV-DLBCL Cancer Data Committee.

Studies are experimental investigations of a particular phenomenon, e.g., case-control studies on a particular trait or cancer research projects reporting matching cancer normal genomes from patients.

Study ID Study Title Study Type
EGAS00001004941 Other

This table displays only public information pertaining to the files in the dataset. If you wish to access this dataset, please submit a request. If you already have access to these data files, please consult the download documentation.

ID File Type Size Quality Report
Located in
i
EGAF00004965362 fastq.gz 65.9 MB Report
EGAF00004965363 fastq.gz 66.2 MB Report
EGAF00004965364 fq.gz 23.1 GB Report
EGAF00004965365 fq.gz 27.0 GB Report
EGAF00004965366 fq.gz 23.6 GB Report
EGAF00004965367 fq.gz 27.2 GB Report
EGAF00004965368 fq.gz 47.3 GB Report
EGAF00004965369 fq.gz 55.8 GB Report
EGAF00004965370 fq.gz 25.2 GB Report
EGAF00004965371 fq.gz 30.0 GB Report
EGAF00004965372 fq.gz 25.0 GB Report
EGAF00004965373 fq.gz 30.0 GB Report
EGAF00004965374 fastq.gz 152.6 MB Report
EGAF00004965375 fastq.gz 158.1 MB Report
EGAF00004965376 fastq.gz 223.5 MB Report
EGAF00004965377 fastq.gz 228.3 MB Report
EGAF00004965378 fq.gz 24.9 GB Report
EGAF00004965379 fq.gz 29.0 GB Report
EGAF00004965380 fastq.gz 206.5 MB Report
EGAF00004965381 fastq.gz 210.9 MB Report
EGAF00004965382 fastq.gz 119.4 MB Report
EGAF00004965383 fastq.gz 124.5 MB Report
EGAF00004965384 fastq.gz 88.3 MB Report
EGAF00004965385 fastq.gz 86.4 MB Report
EGAF00004965386 fq.gz 25.7 GB Report
EGAF00004965387 fq.gz 28.1 GB Report
EGAF00004965388 fastq.gz 116.0 MB Report
EGAF00004965389 fastq.gz 119.0 MB Report
EGAF00004965390 fastq.gz 199.9 MB Report
EGAF00004965391 fastq.gz 207.8 MB Report
EGAF00004965392 fastq.gz 201.1 MB Report
EGAF00004965393 fastq.gz 206.7 MB Report
EGAF00004965394 fastq.gz 230.3 MB Report
EGAF00004965395 fastq.gz 235.6 MB Report
EGAF00004965396 fastq.gz 203.7 MB Report
EGAF00004965397 fastq.gz 209.7 MB Report
EGAF00004965398 fastq.gz 184.0 MB Report
EGAF00004965399 fastq.gz 190.4 MB Report
EGAF00004965400 fastq.gz 124.2 MB Report
EGAF00004965401 fastq.gz 126.4 MB Report
EGAF00004965402 fastq.gz 177.7 MB Report
EGAF00004965403 fastq.gz 191.2 MB Report
EGAF00004965404 fastq.gz 180.6 MB Report
EGAF00004965405 fastq.gz 171.2 MB Report
EGAF00004965406 fastq.gz 209.3 MB Report
EGAF00004965407 fastq.gz 209.7 MB Report
EGAF00004965408 fq.gz 23.3 GB Report
EGAF00004965409 fq.gz 27.2 GB Report
EGAF00004965410 fq.gz 21.5 GB Report
EGAF00004965411 fq.gz 24.7 GB Report
EGAF00004965412 fastq.gz 137.7 MB Report
EGAF00004965413 fastq.gz 142.2 MB Report
EGAF00004965414 fastq.gz 91.8 MB Report
EGAF00004965415 fastq.gz 92.2 MB Report
EGAF00004965416 fastq.gz 268.8 MB Report
EGAF00004965417 fastq.gz 271.3 MB Report
EGAF00004965418 fastq.gz 246.8 MB Report
EGAF00004965419 fastq.gz 16 Bytes
EGAF00004965420 fastq.gz 123.2 MB Report
EGAF00004965421 fastq.gz 123.9 MB Report
EGAF00004965422 fastq.gz 125.9 MB Report
EGAF00004965423 fastq.gz 127.2 MB Report
EGAF00004965424 fq.gz 24.1 GB Report
EGAF00004965425 fq.gz 29.3 GB Report
EGAF00004965426 fq.gz 24.4 GB Report
EGAF00004965427 fq.gz 28.9 GB Report
EGAF00004965428 fq.gz 24.4 GB Report
EGAF00004965429 fq.gz 28.1 GB Report
EGAF00004965430 fq.gz 20.9 GB Report
EGAF00004965431 fq.gz 24.5 GB Report
EGAF00004965432 fastq.gz 176.0 MB Report
EGAF00004965433 fastq.gz 177.2 MB Report
EGAF00004965434 fq.gz 44.2 GB Report
EGAF00004965435 fq.gz 51.4 GB Report
EGAF00004965436 fq.gz 22.1 GB Report
EGAF00004965437 fq.gz 25.5 GB Report
EGAF00004965438 fq.gz 23.4 GB Report
EGAF00004965439 fq.gz 25.3 GB Report
EGAF00004965440 fastq.gz 161.1 MB Report
EGAF00004965441 fastq.gz 168.0 MB Report
EGAF00004965442 fastq.gz 201.3 MB Report
EGAF00004965443 fastq.gz 200.2 MB Report
EGAF00004965444 fastq.gz 61.7 MB Report
EGAF00004965445 fastq.gz 68.5 MB Report
EGAF00004965446 fastq.gz 207.2 MB Report
EGAF00004965447 fastq.gz 205.5 MB Report
EGAF00004965448 fastq.gz 88.8 MB Report
EGAF00004965449 fastq.gz 85.2 MB Report
EGAF00004965450 fastq.gz 61.7 MB Report
EGAF00004965451 fastq.gz 60.7 MB Report
EGAF00004965452 fastq.gz 173.0 MB Report
EGAF00004965453 fastq.gz 176.7 MB Report
EGAF00004965454 fastq.gz 55.7 MB Report
EGAF00004965455 fastq.gz 55.0 MB Report
EGAF00004965456 fastq.gz 87.4 MB Report
EGAF00004965457 fastq.gz 88.9 MB Report
EGAF00004965458 fastq.gz 209.6 MB Report
EGAF00004965459 fastq.gz 217.6 MB Report
EGAF00004965460 fastq.gz 86.8 MB Report
EGAF00004965461 fastq.gz 87.2 MB Report
EGAF00004965462 fastq.gz 178.0 MB Report
EGAF00004965463 fastq.gz 183.8 MB Report
EGAF00004965464 fastq.gz 176.9 MB Report
EGAF00004965465 fastq.gz 185.2 MB Report
EGAF00004965466 fastq.gz 233.3 MB Report
EGAF00004965467 fastq.gz 246.5 MB Report
EGAF00004965468 fastq.gz 215.4 MB Report
EGAF00004965469 fastq.gz 217.2 MB Report
EGAF00004965470 fastq.gz 70.5 MB Report
EGAF00004965471 fastq.gz 71.4 MB Report
EGAF00004965472 fastq.gz 197.3 MB Report
EGAF00004965473 fastq.gz 201.9 MB Report
EGAF00004965474 fastq.gz 45.6 MB Report
EGAF00004965475 fastq.gz 47.7 MB Report
EGAF00004965476 fastq.gz 97.3 MB Report
EGAF00004965477 fastq.gz 100.0 MB Report
EGAF00004965478 fastq.gz 181.4 MB Report
EGAF00004965479 fastq.gz 183.5 MB Report
EGAF00004965480 fastq.gz 179.6 MB Report
EGAF00004965481 fastq.gz 183.7 MB Report
EGAF00004965482 fastq.gz 162.9 MB Report
EGAF00004965483 fastq.gz 162.9 MB Report
EGAF00004965484 fastq.gz 45.4 MB Report
EGAF00004965485 fastq.gz 47.9 MB Report
EGAF00004965486 fastq.gz 188.1 MB Report
EGAF00004965487 fastq.gz 196.5 MB Report
126 Files (929.3 GB)